New Findings in Xenografts Described from Peking University Cancer Hospital and Institute ([<superscript>177</superscript>lu]Lu-labeled Anti-claudin-18.2 Antibody Demonstrated Radioimmunotherapy Potential In Gastric Cancer Mouse Xenograft Models).
In: Immunotherapy Weekly, 2024-01-12, S. 401-401
serialPeriodical
Zugriff:
A recent study conducted at Peking University Cancer Hospital and Institute in Beijing, China, has explored the potential of a CLDN18.2-targeted radioimmunotherapy probe as a treatment option for gastric cancer (GC). The study found that the probe, [Lu-177]Lu-TST001, demonstrated specific and high tumor uptake in CLDN18.2-positive xenografts of GC mouse models. Survival studies showed that a low dose of 5.55 MBq and a high dose of 11.10 MBq of [Lu-177]Lu-TST001 significantly inhibited tumor growth compared to the control group. The research concluded that [Lu-177]Lu-TST001 exhibits strong potential for clinical translation and provides a promising treatment option for CLDN18.2-overexpressing tumors, including GC. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
New Findings in Xenografts Described from Peking University Cancer Hospital and Institute ([<superscript>177</superscript>lu]Lu-labeled Anti-claudin-18.2 Antibody Demonstrated Radioimmunotherapy Potential In Gastric Cancer Mouse Xenograft Models).
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2024-01-12, S. 401-401 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Sonstiges: |
|